Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S.
May 03 2022 - 6:00AM
Business Wire
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare
leader developing and producing patented Microcyn® technology-based
stabilized hypochlorous acid (HOCl) products for a wide range of
applications, including wound, eye, oral and nasal care,
dermatological conditions and disinfectant use, and its partner,
the MicroSafe Group DMCC, received EPA approval for Nanocyn® as a
hospital-grade disinfectant in the United States. Nanocyn®, which
is manufactured by Sonoma using its patented Microcyn® Technology,
is a ready to use hard-surface disinfectant that may reduce the
risk of infection by treating hard, non-porous surfaces, making it
especially useful in high-risk areas such as hospitals, schools,
mass transit, and care facilities.
Nanocyn® hospital-grade disinfectant is currently sold by
MicroSafe Group in Europe, the Middle East/West Africa and
Australia. Nanocyn has been proven to kill a variety of bacteria,
such as Staphylococcus aureus and Pseudomonas aeruginosa, and has a
30 second kill time for many viruses, including norovirus, on hard
non-porous surfaces. In May 2020, Nanocyn was entered into the
Australian Register of Therapeutic Goods (ARTG) for use against
SARS-CoV-2 (COVID-19). Nanocyn utilizes Sonoma’s patented Microcyn
technology which has a long, proven record of significantly
reducing numerous bacteria, viruses, fungi and spores on many
surfaces. For more information see
www.sonomapharma.com/literature/.
The EPA approval process was a coordinated effort by Sonoma and
MicroSafe Group. MicroSafe Group managed and financed the
regulatory process with the EPA in exchange for non-exclusive
rights to distribute Nanocyn in the United States. Sonoma provided
expertise and manufactured the required product samples.
“The MicroSafe Group is very pleased with the EPA approval of
Nanocyn® hospital-grade disinfectant, known as MicroSafe®
disinfectant in Europe, the Middle East/West Africa and Australia.
The EPA approval validates over 20 years of research, development
and independent testing that determines the unique stability and
efficacy of Microcyn® Technology, a revolution in stable HOCl,”
said Safwan Abdallah, COO of the MicroSafe Group. “Furthermore,
Nanocyn®’s extraordinarily low toxicity profile as categorized by
the EPA (lowest Category IV per 40 CFR 156.62) means that the
product does not have special handling or disposal requirements.
These features, in combination with its impressive kill time of
viruses on treated hard non-porous surfaces, may make it a game
changer in the realm of infection control,” Safwan continued.
“We are excited to bring our successful partnership with
MicroSafe Group to the United States,” said Amy Trombly, CEO of
Sonoma. “We believe Nanocyn® hospital-grade disinfectant has
countless applications due to its efficacy and safety profile, and
we are eager to play a role to help curb the spread of infectious
disease here in the United States and globally.”
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for
developing and producing stabilized hypochlorous acid (HOCl)
products for a wide range of applications, including wound care,
animal health care, eye care, nasal care, oral care, and
dermatological conditions. The company’s products reduce
infections, itch, pain, scarring and harmful inflammatory responses
in a safe and effective manner. In-vitro and clinical studies of
hypochlorous acid (HOCl) show it to have impressive antipruritic,
antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s
stabilized HOCl immediately relieves itch and pain, kills pathogens
and breaks down biofilm, does not sting or irritate skin and
oxygenates the cells in the area treated assisting the body in its
natural healing process. The company’s products are sold either
directly or via partners in 54 countries worldwide and the company
actively seeks new distribution partners. The company has offices
in Woodstock, Georgia, and Boulder, Colorado, as well as
manufacturing operations in Latin America. European marketing and
sales are headquartered in Roermond, Netherlands. More information
can be found at www.sonomapharma.com. For partnership
opportunities, please contact busdev@sonomapharma.com.
About MicroSafe Group
The MicroSafe Group has operations internationally with its head
office in Dubai, United Arab Emirates. With regional offices in the
Middle East, as well as MicroSafe Care Australia and Canada,
MicroSafe Group is providing innovative solutions to a wide range
of industries and healthcare providers. The MicroSafe Group
promotes only products it believes will truly revolutionize
healthcare – products that will enrich the lives of patients and
healthcare professionals all over the world. Interested
distributors for Europe, West Asia and North Africa may contact
Safwan Abdallah, COO of MicroSafe Group at info@microsafecare.com.
For Australia please contact MicroSafe Australia’s Managing
Director Matt Seifert, at info@microsafe.com.au. More information
can be found at www.microsafe.com and www.microsafe.com.au.
Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release are forward-looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial and
technology progress and future financial performance of Sonoma
Pharmaceuticals, Inc. and its subsidiaries (the “company”). These
forward-looking statements are identified by the use of words such
as “continue,” “expect,” “promise,” and “expand,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the company’s business
that could cause actual results to vary, including such risks
resulting from the global COVID-19 pandemic, that regulatory
clinical and guideline developments may change, scientific data may
not be sufficient to meet regulatory standards or receipt of
required regulatory clearances or approvals, clinical results may
not be replicated in actual patient settings, protection offered by
the company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the company’s products will not be as large as expected,
the company’s products will not be able to penetrate one or more
targeted markets, revenues will not be sufficient to meet the
company’s cash needs, fund further development and clinical
studies, as well as uncertainties relative to varying product
formulations and a multitude of diverse regulatory and marketing
requirements in different countries and municipalities, and other
risks detailed from time to time in the company’s filings with the
Securities and Exchange Commission. The company disclaims any
obligation to update these forward-looking statements, except as
required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or
registered trademarks of Sonoma Pharmaceuticals, Inc. All other
trademarks and service marks are the property of their respective
owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220503005592/en/
Media and Investor Contact: Sonoma Pharmaceuticals,
Inc. ir@sonomapharma.com
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sonoma Pharmaceuticals (NASDAQ:SNOA)
Historical Stock Chart
From Apr 2023 to Apr 2024